Predicting Individualized Lung Disease Progression in Treatment-Naive Patients With Lymphangioleiomyomatosis

医学 DLCO公司 淋巴管平滑肌瘤病 扩散能力 自然史 队列 内科学 肺移植 接收机工作特性 间质性肺病 肺功能测试 肺功能 心脏病学
作者
A. Palipana,Emrah Gecili,Seongho Song,Simon R. Johnson,Rhonda D. Szczesniak,Nishant Gupta
出处
期刊:Chest [Elsevier]
卷期号:163 (6): 1458-1470 被引量:1
标识
DOI:10.1016/j.chest.2022.12.027
摘要

Lung function decline varies significantly in patients with lymphangioleiomyomatosis (LAM), impeding individualized clinical decision-making.Can we aid individualized decision-making in LAM by developing a dynamic prediction model that can estimate the probability of clinically relevant FEV1 decline in patients with LAM before treatment initiation?Patients observed in the US National Heart, Lung, and Blood Institute (NHLBI) Lymphangioleiomyomatosis Registry were included. Using routinely available variables such as age at diagnosis, menopausal status, and baseline lung function (FEV1 and diffusing capacity of the lungs for carbon monoxide [Dlco]), we used novel stochastic modeling and evaluated predictive probabilities for clinically relevant drops in FEV1. We formed predictive probabilities of transplant-free survival by jointly modeling longitudinal FEV1 and lung transplantation or death events. External validation used the UK Lymphangioleiomyomatosis Natural History cohort.Analysis of the NHLBI Lymphangioleiomyomatosis Registry and UK Lymphangioleiomyomatosis Natural History cohorts consisted of 216 and 185 individuals, respectively. We derived a joint model that accurately estimated the risk of future lung function decline and 5-year probabilities of transplant-free survival in patients with LAM not taking sirolimus (area under the receiver operating characteristic curve [AUC], approximately 0.80). The prediction model provided estimates of forecasted FEV1, rate of FEV1 decline, and probabilities for risk of prolonged drops in FEV1 for untreated patients with LAM with a high degree of accuracy (AUC > 0.80) for the derivation cohort as well as the validation cohort. Our tool is freely accessible at: https://anushkapalipana.shinyapps.io/testapp_v2/.Longitudinal modeling of routine clinical data can allow individualized LAM prognostication and assist in decision-making regarding the timing of treatment initiation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
milkcoffe发布了新的文献求助10
1秒前
1秒前
2秒前
董可以完成签到,获得积分20
3秒前
4秒前
4秒前
zzy完成签到,获得积分10
6秒前
无感发布了新的文献求助20
6秒前
8秒前
8秒前
zzy发布了新的文献求助10
9秒前
小小怪完成签到 ,获得积分10
11秒前
请叫我过儿完成签到,获得积分20
12秒前
科研发布了新的文献求助20
12秒前
14秒前
爆米花应助天天扫大街采纳,获得10
16秒前
milkcoffe完成签到,获得积分10
17秒前
Akim应助11采纳,获得10
17秒前
19秒前
19秒前
Jhyyy88完成签到,获得积分10
20秒前
22秒前
文献求助发布了新的文献求助10
24秒前
Orange应助呆瓜采纳,获得10
26秒前
水尽云生处完成签到,获得积分10
27秒前
星辰完成签到,获得积分10
28秒前
wangjingli666应助蓝胖子采纳,获得10
30秒前
李爱国应助文献求助采纳,获得10
31秒前
33秒前
虫虫发布了新的文献求助10
34秒前
34秒前
38秒前
英俊的铭应助香草冰淇淋采纳,获得10
39秒前
和谐宛完成签到,获得积分10
39秒前
39秒前
41秒前
从容芮应助小肚溜圆采纳,获得30
42秒前
46秒前
47秒前
我是老大应助Huang采纳,获得10
51秒前
高分求助中
请在求助之前详细阅读求助说明!!!! 20000
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
Sphäroguß als Werkstoff für Behälter zur Beförderung, Zwischen- und Endlagerung radioaktiver Stoffe - Untersuchung zu alternativen Eignungsnachweisen: Zusammenfassender Abschlußbericht 1000
Yuwu Song, Biographical Dictionary of the People's Republic of China 700
[Lambert-Eaton syndrome without calcium channel autoantibodies] 520
The Three Stars Each: The Astrolabes and Related Texts 500
Additive Manufacturing Design and Applications 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2467425
求助须知:如何正确求助?哪些是违规求助? 2135548
关于积分的说明 5441474
捐赠科研通 1860416
什么是DOI,文献DOI怎么找? 925272
版权声明 562645
科研通“疑难数据库(出版商)”最低求助积分说明 495006